BioAffinity Technologies Receivables

The latest receivables for BIAF is $690K as of March 2026. That compares with $960K in the prior-year period — down 28.9% year over year. Investors often review this figure alongside BioAffinity Technologies's historical trend and sector peers before judging valuation or financial health.

Over the past year, BIAF's receivables moved from $960K to $690K — a 28.9% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in BioAffinity Technologies's operating scale or balance-sheet position.

A receivables figure of $690K for BIAF is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. Explore the charts below for those layers of context.

After noting BIAF's receivables ($690K), review year-over-year change from $960K, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.